UK Markets closed

NuCana plc (NCNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6500+0.1500 (+10.00%)
At close: 04:00PM EDT
1.6700 +0.02 (+1.21%)
After hours: 06:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5000
Open1.5300
Bid1.6500 x 1800
Ask1.6800 x 1200
Day's range1.5300 - 1.6703
52-week range0.5170 - 3.3200
Volume165,310
Avg. volume319,500
Market cap86.097M
Beta (5Y monthly)0.38
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

    EDINBURGH, United Kingdom, July 27, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is

  • Globe Newswire

    German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent

    EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the “Court”) issued a judgement on July 7, 2022 that Gilead Sciences Ireland UC and Gilead Sciences GmbH (together, “Gilead”) infringe NuCana’s composition of matter claims in European Patent 2955190 (the “’190 patent”) through their sales of Sovaldi®, Harvoni®, Vosevi® and Epclusa® in Germany. This judgement f

  • Globe Newswire

    NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

    NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors EDINBURGH, United Kingdom, June 10, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data to be presented at the European Hematology Association (EHA) 2022 Hybrid Congress highlighting the activity of NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA), in a broad range of